Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of 177Lu-HTK03170 in Metastatic, Castration-Resistant Prostate Cancer Subjects With Prostate-specific Membrane Antigen-positive Disease

NCT05570994 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT05570994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05570994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of 177Lu-HTK03170 in Metastatic, Castration-Resistant Prostate Cancer Subjects With Prostate-specific Membrane Antigen-positive Disease
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
January 1, 2024
Completion date
May 1, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, metastatic castration-resistant prostate cancer, prostate cancer metastatic